查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2117038

寡核苷酸治療市場：全球產業分析、市場規模、市佔率及2026年至2033年預測（依寡核苷酸類型、應用、遞送系統、最終用戶、給藥途徑、國家及地區分類）

Oligonucleotide Therapeutics Market, By Oligonucleotide Class, By Application, By Delivery System, By End User, By Route of Administration, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2026-2033
出版日期: | 出版商: AnalystView Market Insights | 英文 381 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

預計到 2025 年，寡核苷酸療法市場價值將達到 71.802 億美元，並預計從 2026 年到 2033 年以 20.3% 的複合年成長率成長。

寡核苷酸療法是一種基於DNA或RNA的化學工程藥物，它透過特定的分子間相互作用來調節基因表現或RNA功能。此市場涵蓋反義寡核苷酸、小干擾RNA（siRNA）、基於微型RNA（miRNA）的藥物、適配體、核酶、免疫刺激性寡核苷酸、複合物及相關創新技術，以及相關的合成、生產、分析和服務。這些產品旨在治療多種疾病，包括罕見疾病、神經系統疾病、代謝性疾病、心血管疾病、腎臟疾病、感染疾病和癌症。

在邁向商業化的研發過程中，骨架和糖基化修飾、序列設計、結合策略、雜質控制和分析檢驗等設計創新變得日益重要。 FDA計劃在2025年前批准46種新藥，反映出法規環境對更多樣化和更複雜的治療方法的接受度不斷提高。整體，寡核苷酸療法領域正從技術開發階段邁向一個階段，該階段旨在開發出作用機制更明確、針對不同疾病標靶的更具可預測性的藥物類別。

寡核苷酸治療藥物市場—市場動態

遞送技術的進步正在擴大基因靜默療法的應用範圍。

遞送技術的創新使得寡核苷酸療法能夠針對過去難以觸及的組織，進而增強藥物的治療效果。化學修飾、配體結合聚合物、重構修飾和其他最尖端科技正在改善寡核苷酸的藥物動力學特性、細胞內進入機制、組織分佈和停留時間，從而拓展其臨床應用範圍和療效。這些遞送技術進步最重要的應用領域包括神經系統、腎臟、代謝系統和心血管系統疾病。 2025年，FDA批准了三種不同的寡核苷酸療法——fitsilan、donidalorsen和prozasilan——這表明監管機構對這些藥物的持續關注。從這個角度來看，為了充分發揮序列特異性藥物的治療潛力並應對多種疾病，需要拓展針對不同作用機制的療法。

寡核苷酸治療藥物市場—區域洞察

北美仍然是寡核苷酸療法發展的關鍵區域，這得益於其生物技術生態系統、轉化和臨床專業知識、監管和學術能力以及先進的製造和供應鏈網路。美國的藥物開發環境為企業提供了接觸RNA研發公司、合約研發生產機構（CDMO）、分析和研究機構以及投資者的機會，這些機構和投資者能夠應對標靶發現的挑戰，並將分子推進到臨床試驗階段，同時還擁有大規模的臨床試驗基礎設施。根據ClinicalTrials.gov網站預測，到2025年，預計將有42,966項研究首次發表，不限適應症。對於寡核苷酸研發公司而言，美國成熟的臨床和轉化生態系統提供了重要的支持，並縮短了此類複雜研發計畫的學習曲線。

歐洲是寡核苷酸研發的關鍵區域，其法規環境不僅促進了複雜分子的研究，也為深入了解罕見疾病和遺傳疾病的多種機制提供了重要視角。歐洲藥品管理局 (EMA) 透過發布寡核苷酸療法各方面的指南，支持這些複雜分子的研發，這些指南涵蓋合成、結合、表徵、分析控制和品質要求等各個方面。歐洲的法規環境促進了從罕見疾病和神經肌肉疾病到眼科疾病和代謝性疾病等廣泛遺傳疾病領域的研究。 2025 年，EMA 授予一種靶向 ABCA4 前體 mRNA 的反義寡核苷酸治療遺傳性視網膜營養不良的孤兒藥資格，這反映了歐洲在該領域的監管和科研投入。

目錄

第1章 寡核苷酸治療藥物市場概述

  • 分析範圍
  • 市場估算期

第2章執行摘要

  • 市場區隔
  • 競爭考察

第3章：寡核苷酸療法的關鍵市場趨勢

  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 未來市場趨勢

第4章：寡核苷酸治療藥物產業的分析

  • PEST分析
  • 波特五力分析
  • 市場成長前景展望圖
  • 管理體制分析

第5章：寡核苷酸治療市場：地緣政治緊張局勢加劇的影響

  • 新冠疫情的影響
  • 俄烏戰爭的影響
  • 中東衝突的影響

第6章：寡核苷酸治療藥物的市場趨勢

  • 寡核苷酸治療藥物市佔分析，2025年
  • 主要製造商的細分數據
    • 對現有公司的分析
    • 新興企業分析

第7章 寡核苷酸治療市場：依寡核苷酸類型分類

  • 概述
    • 片段佔有率分析：依寡核苷酸類型
    • 反義寡核苷酸（ASO）
    • 小干擾RNA（siRNA/RNAi）
    • 微型RNA（miRNA）
    • 適體
    • CpG寡核苷酸
    • 核糖核酸酶
    • 其他

第8章 寡核苷酸治療市場：依應用領域分類

  • 概述
    • 基於細分市場的市場佔有率分析：按應用領域
    • 神經病變
    • 心血管代謝疾病
    • 腫瘤學
    • 感染疾病
    • 腎臟/腎病
    • 眼科
    • 其他

第9章 寡核苷酸治療市場：依遞送系統分類

  • 概述
    • 細分市場佔有率分析：依配送系統分類
    • 脂質奈米顆粒（LNPs）
    • GalNAc綴合物
    • 胜肽綴合物
    • 基於聚合物的遞送系統
    • 其他組合/輸送系統

第10章 寡核苷酸治療市場：依最終使用者分類

  • 概述
    • 基於細分市場的市場佔有率分析：按最終用戶分類
    • 製藥和生物技術公司
    • 醫院和專科診所
    • 學術研究機構
    • 受託研究機構（CRO）
    • 其他

第11章 寡核苷酸治療市場：依給藥途徑分類

  • 概述
    • 基於細分市場的市佔率分析：按給藥途徑
    • 皮下
    • 靜脈
    • 脊髓腔內部
    • 肌肉內部
    • 其他

第12章 寡核苷酸治療市場：依地區分類

  • 介紹
  • 北美洲
    • 概述
    • 主要製造商：北美
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • 主要製造商：歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 瑞典
    • 俄羅斯
    • 波蘭
    • 丹麥
    • 其他歐洲國家
  • 亞太地區
    • 概述
    • 主要製造商：亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 菲律賓
    • 台灣
    • 越南
    • 其他亞太國家
  • 拉丁美洲
    • 概述
    • 主要製造商：拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 其他拉丁美洲國家
  • 中東和非洲
    • 概述
    • 主要生產商：中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 土耳其
    • 阿爾及利亞
    • 埃及
    • 伊朗
    • 卡達
    • 其他中東和非洲國家

第13章：主要供應商分析：寡核苷酸治療產業

  • 競爭基準
    • 競爭對手儀錶板
    • 競爭定位
  • 公司簡介
    • Ionis Pharmaceuticals, Inc.
    • Alnylam Pharmaceuticals, Inc.
    • Sarepta Therapeutics, Inc.
    • Biogen Inc.
    • Novartis AG
    • Arrowhead Pharmaceuticals, Inc.
    • Roche/Genentech
    • Astellas Pharma Inc.
    • Nippon Shinyaku Co., Ltd.
    • Amgen Inc.
    • Regeneron Pharmaceuticals, Inc.
    • BioMarin Pharmaceutical Inc.
    • Moderna, Inc.
    • Wave Life Sciences Ltd.
    • Arcturus Therapeutics Holdings Inc.
    • Avidity Biosciences, Inc.
    • Silence Therapeutics plc
    • Nitto Denko Corporation/Nitto Denko Avecia
    • Stoke Therapeutics, Inc.
    • Others

第14章：AnalystView 的全景視圖

簡介目錄
Product Code: ANV7311

Oligonucleotide Therapeutics Market size was valued at US$ 7,180.2 Million in 2025, expanding at a CAGR of 20.3% from 2026 to 2033.

Oligonucleotide therapeutics represent a class of chemically engineered DNA or RNA-based drugs that modulate gene expression or RNA function through specific molecular interactions. The market includes antisense oligonucleotides, small interfering RNA, microRNA-based pharmaceuticals, aptamers, ribozymes, immunostimulatory oligonucleotides, conjugates, and related innovative technologies, as well as accompanying synthesis, production, analysis, and services. The products are intended for the treatment of a wide range of diseases, including orphan, neurologic, metabolic, cardiovascular, renal, infectious diseases, and cancer.

A growing emphasis is placed on design innovations such as backbone and sugar modifications, sequence design, conjugation strategies, control of impurities, and analytical validation for commercial development. In 2025, the FDA approved 46 new drugs, reflecting increased acceptance in the broader regulatory environment for more varied and complex therapeutic approaches. Overall, the field of oligonucleotide therapeutics is transitioning from a phase of technology development to one of generating more predictable drug category with specific mechanisms of action for a variety of disease targets.

Oligonucleotide Therapeutics Market- Market Dynamics

Advances in Delivery Are Expanding the Reach of Gene-Silencing Therapies

Innovations in delivery methodologies are now enabling oligonucleotide therapies to target previously inaccessible tissues and increase the drugs' therapeutic efficacy. Chemical modifications, ligand-conjugated polymers, backbone alterations, and other cutting-edge technologies can improve oligonucleotides' pharmacokinetic properties, cellular entry mechanisms, tissue distribution, and persistence, thereby increasing their clinical performance and range of applications. The most critical applications for such delivery advancements include neurological, renal, metabolic, and cardiovascular indications. During the year 2025, the FDA approved three different oligonucleotide therapies: fitusiran, donidalorsen, and plozasiran, confirming the regulators' ongoing interest in the medicinal products. From this perspective, an expanded number of modalities across diverse mechanisms are required to harness the therapeutic potential of sequence-specific drugs fully and further address a wide range of medical conditions.

Oligonucleotide Therapeutics Market- Geographical Insights

North America remains a key development region for oligonucleotide therapeutics, driven by the presence of biotech ecosystems, translational clinical expertise, regulatory and academic capabilities, and advanced manufacturing and supply networks. The U.S. drug development landscape offers access to RNA-focused developers, CDMOs, analytical and research organizations, and investors who can help navigate the challenges of target discovery and bring the molecule through clinical trials, as well as a large clinical trials infrastructure. According to ClinicalTrials.gov, in 2025, there were 42,966 studies first posted during the year across indications. For oligonucleotide developers, the well-established U.S. clinical and translational ecosystem can provide critical support and shorten the learning curve of such complex R&D projects.

Europe is an important region for oligonucleotide development, with a regulatory environment that fosters work on complex molecules while also providing critical insights into rare diseases and diverse mechanisms of genetic diseases. The European Medicines Agency (EMA) has published guidance on various aspects of oligonucleotide therapeutics, including synthesis, conjugation, characterization, analytical control, and quality requirements, supporting the development of such complex molecules. The regulatory environment in Europe fosters work on a wide range of genetic disease areas-from rare diseases and neuromuscular disorders to ophthalmology and metabolic diseases. In 2025, the EMA granted orphan designation to an antisense oligonucleotide targeting ABCA4 pre-mRNA for the treatment of inherited retinal dystrophy, demonstrating Europe's regulatory and scientific commitment to the field.

Oligonucleotide Therapeutics Market- Competitive Landscape:

Competition in the oligonucleotide therapeutics sector is intensifying, with industry players focusing on the differentiation of their platforms, the breadth of delivery approaches, the execution of trials, and control over manufacturing to obtain an advantage. Alnylam is a major player in the RNA interference space; Ionis has broad antisense experience, and Arrowhead, Avidity, and ProQR have diversified approaches to delivery, conjugation, and RNA modulation. Control over manufacturing is also a critical success factor due to the complexity of sequence design, impurities, conjugation, and analytical release. In 2025, Alnylam expects to have three Phase III programs, which shows that the company continues to advance its pipeline. Thus, for the most part, competition is driven by the combination of successful delivery vehicles, development, and manufacturing expertise.

Recent Developments:

In December 2025, Alnylam Pharmaceuticals announced the expansion of its RNAi manufacturing infrastructure in Norton, Massachusetts. With this new project, Alnylam aims to increase the production capacities of siRNA-based medications by enhancing the organization's core competencies in drug manufacturing.

In October 2025, ProQR Therapeutics announced the first European regulatory approval to advance in the clinical trial stage of its investigational RNA-editing therapeutic candidate, AX-0810. The company's intention is to target the NTCP gene for the treatment of cholestatic diseases using an innovative RNA-editing approach. This new development allows the company to initiate a Phase 1 study of the drug category.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Ionis Pharmaceuticals, Inc.
  • Alnylam Pharmaceuticals, Inc.
  • Sarepta Therapeutics, Inc.
  • Biogen Inc.
  • Novartis AG
  • Arrowhead Pharmaceuticals, Inc.
  • Roche / Genentech
  • Astellas Pharma Inc.
  • Nippon Shinyaku Co., Ltd.
  • Amgen Inc.
  • Regeneron Pharmaceuticals, Inc.
  • BioMarin Pharmaceutical Inc.
  • Moderna, Inc.
  • Wave Life Sciences Ltd.
  • Arcturus Therapeutics Holdings Inc.
  • Avidity Biosciences, Inc.
  • Silence Therapeutics plc
  • Nitto Denko Corporation / Nitto Denko Avecia
  • Stoke Therapeutics, Inc.
  • Others

GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET, BY OLIGONUCLEOTIDE CLASS- MARKET ANALYSIS, 2020 - 2033

  • Antisense Oligonucleotides (ASOs)
  • Small Interfering RNA (siRNA / RNAi)
  • microRNA (miRNA)
  • Aptamers
  • CpG Oligonucleotides
  • Ribozymes
  • Others

GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET, BY APPLICATION- MARKET ANALYSIS, 2020 - 2033

  • Neurological Disorders
  • Cardiometabolic Disorders
  • Oncology
  • Infectious Diseases
  • Kidney / Renal Diseases
  • Ophthalmology
  • Others

GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET, BY DELIVERY SYSTEM- MARKET ANALYSIS, 2020 - 2033

  • Lipid Nanoparticles (LNPs)
  • GalNAc Conjugates
  • Peptide Conjugates
  • Polymer-Based Delivery Systems
  • Other Conjugates / Delivery Systems

GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET, BY END USER- MARKET ANALYSIS, 2020 - 2033

  • Pharmaceutical & Biotechnology Companies
  • Hospitals & Specialty Clinics
  • Academic & Research Institutes
  • Contract Research Organizations (CROs)
  • Others

GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2020 - 2033

  • Subcutaneous
  • Intravenous
  • Intrathecal
  • Intramuscular
  • Others

GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET, BY REGION- MARKET ANALYSIS, 2020 - 2033

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Denmark
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Taiwan
  • Vietnam
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Iran
  • Qatar
  • Rest of MEA

Table of Contents

1. Oligonucleotide Therapeutics Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
  • 2.2. Competitive Insights

3. Oligonucleotide Therapeutics Key Market Trends

  • 3.1. Oligonucleotide Therapeutics Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Oligonucleotide Therapeutics Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Oligonucleotide Therapeutics Market Opportunities
  • 3.4. Oligonucleotide Therapeutics Market Future Trends

4. Oligonucleotide Therapeutics Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Oligonucleotide Therapeutics Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Oligonucleotide Therapeutics Market Landscape

  • 6.1. Oligonucleotide Therapeutics Market Share Analysis, 2025
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Oligonucleotide Therapeutics Market - By Oligonucleotide Class

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Oligonucleotide Class, 2025 & 2033 (%)
    • 7.1.2. Antisense Oligonucleotides (ASOs)
    • 7.1.3. Small Interfering RNA (siRNA / RNAi)
    • 7.1.4. microRNA (miRNA)
    • 7.1.5. Aptamers
    • 7.1.6. CpG Oligonucleotides
    • 7.1.7. Ribozymes
    • 7.1.8. Others

8. Oligonucleotide Therapeutics Market - By Application

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Application, 2025 & 2033 (%)
    • 8.1.2. Neurological Disorders
    • 8.1.3. Cardiometabolic Disorders
    • 8.1.4. Oncology
    • 8.1.5. Infectious Diseases
    • 8.1.6. Kidney / Renal Diseases
    • 8.1.7. Ophthalmology
    • 8.1.8. Others

9. Oligonucleotide Therapeutics Market - By Delivery System

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Delivery System, 2025 & 2033 (%)
    • 9.1.2. Lipid Nanoparticles (LNPs)
    • 9.1.3. GalNAc Conjugates
    • 9.1.4. Peptide Conjugates
    • 9.1.5. Polymer-Based Delivery Systems
    • 9.1.6. Other Conjugates / Delivery Systems

10. Oligonucleotide Therapeutics Market - By End User

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By End User, 2025 & 2033 (%)
    • 10.1.2. Pharmaceutical & Biotechnology Companies
    • 10.1.3. Hospitals & Specialty Clinics
    • 10.1.4. Academic & Research Institutes
    • 10.1.5. Contract Research Organizations (CROs)
    • 10.1.6. Others

11. Oligonucleotide Therapeutics Market - By Route of Administration

  • 11.1. Overview
    • 11.1.1. Segment Share Analysis, By Route of Administration, 2025 & 2033 (%)
    • 11.1.2. Subcutaneous
    • 11.1.3. Intravenous
    • 11.1.4. Intrathecal
    • 11.1.5. Intramuscular
    • 11.1.6. Others

12. Oligonucleotide Therapeutics Market- By Geography

  • 12.1. Introduction
    • 12.1.1. Segment Share Analysis, By Geography, 2025 & 2033 (%)
  • 12.2. North America
    • 12.2.1. Overview
    • 12.2.2. Oligonucleotide Therapeutics Key Manufacturers in North America
    • 12.2.3. North America Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 12.2.4. North America Market Size and Forecast, By Oligonucleotide Class, 2020 - 2033 (US$ Million)
    • 12.2.5. North America Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
    • 12.2.6. North America Market Size and Forecast, By Delivery System, 2020 - 2033 (US$ Million)
    • 12.2.7. North America Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 12.2.8. North America Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 12.2.9. U.S.
      • 12.2.9.1. Overview
      • 12.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.2.9.3. U.S. Market Size and Forecast, By Oligonucleotide Class, 2020 - 2033 (US$ Million)
      • 12.2.9.4. U.S. Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 12.2.9.5. U.S. Market Size and Forecast, By Delivery System, 2020 - 2033 (US$ Million)
      • 12.2.9.6. U.S. Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
      • 12.2.9.7. U.S. Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 12.2.10. Canada
      • 12.2.10.1. Overview
      • 12.2.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.2.10.3. Canada Market Size and Forecast, By Oligonucleotide Class, 2020 - 2033 (US$ Million)
      • 12.2.10.4. Canada Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 12.2.10.5. Canada Market Size and Forecast, By Delivery System, 2020 - 2033 (US$ Million)
      • 12.2.10.6. Canada Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
      • 12.2.10.7. Canada Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
  • 12.3. Europe
    • 12.3.1. Overview
    • 12.3.2. Oligonucleotide Therapeutics Key Manufacturers in Europe
    • 12.3.3. Europe Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 12.3.4. Europe Market Size and Forecast, By Oligonucleotide Class, 2020 - 2033 (US$ Million)
    • 12.3.5. Europe Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
    • 12.3.6. Europe Market Size and Forecast, By Delivery System, 2020 - 2033 (US$ Million)
    • 12.3.7. Europe Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 12.3.8. Europe Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 12.3.9. Germany
      • 12.3.9.1. Overview
      • 12.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.3.9.3. Germany Market Size and Forecast, By Oligonucleotide Class, 2020 - 2033 (US$ Million)
      • 12.3.9.4. Germany Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 12.3.9.5. Germany Market Size and Forecast, By Delivery System, 2020 - 2033 (US$ Million)
      • 12.3.9.6. Germany Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
      • 12.3.9.7. Germany Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 12.3.10. UK
      • 12.3.10.1. Overview
      • 12.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.3.10.3. UK Market Size and Forecast, By Oligonucleotide Class, 2020 - 2033 (US$ Million)
      • 12.3.10.4. UK Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 12.3.10.5. UK Market Size and Forecast, By Delivery System, 2020 - 2033 (US$ Million)
      • 12.3.10.6. UK Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
      • 12.3.10.7. UK Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 12.3.11. France
      • 12.3.11.1. Overview
      • 12.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.3.11.3. France Market Size and Forecast, By Oligonucleotide Class, 2020 - 2033 (US$ Million)
      • 12.3.11.4. France Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 12.3.11.5. France Market Size and Forecast, By Delivery System, 2020 - 2033 (US$ Million)
      • 12.3.11.6. France Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
      • 12.3.11.7. France Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 12.3.12. Italy
      • 12.3.12.1. Overview
      • 12.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.3.12.3. Italy Market Size and Forecast, By Oligonucleotide Class, 2020 - 2033 (US$ Million)
      • 12.3.12.4. Italy Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 12.3.12.5. Italy Market Size and Forecast, By Delivery System, 2020 - 2033 (US$ Million)
      • 12.3.12.6. Italy Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
      • 12.3.12.7. Italy Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 12.3.13. Spain
      • 12.3.13.1. Overview
      • 12.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.3.13.3. Spain Market Size and Forecast, By Oligonucleotide Class, 2020 - 2033 (US$ Million)
      • 12.3.13.4. Spain Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 12.3.13.5. Spain Market Size and Forecast, By Delivery System, 2020 - 2033 (US$ Million)
      • 12.3.13.6. Spain Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
      • 12.3.13.7. Spain Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 12.3.14. The Netherlands
      • 12.3.14.1. Overview
      • 12.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.3.14.3. The Netherlands Market Size and Forecast, By Oligonucleotide Class, 2020 - 2033 (US$ Million)
      • 12.3.14.4. The Netherlands Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 12.3.14.5. The Netherlands Market Size and Forecast, By Delivery System, 2020 - 2033 (US$ Million)
      • 12.3.14.6. The Netherlands Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
      • 12.3.14.7. The Netherlands Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 12.3.15. Sweden
      • 12.3.15.1. Overview
      • 12.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.3.15.3. Sweden Market Size and Forecast, By Oligonucleotide Class, 2020 - 2033 (US$ Million)
      • 12.3.15.4. Sweden Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 12.3.15.5. Sweden Market Size and Forecast, By Delivery System, 2020 - 2033 (US$ Million)
      • 12.3.15.6. Sweden Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
      • 12.3.15.7. Sweden Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 12.3.16. Russia
      • 12.3.16.1. Overview
      • 12.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.3.16.3. Russia Market Size and Forecast, By Oligonucleotide Class, 2020 - 2033 (US$ Million)
      • 12.3.16.4. Russia Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 12.3.16.5. Russia Market Size and Forecast, By Delivery System, 2020 - 2033 (US$ Million)
      • 12.3.16.6. Russia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
      • 12.3.16.7. Russia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 12.3.17. Poland
      • 12.3.17.1. Overview
      • 12.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.3.17.3. Poland Market Size and Forecast, By Oligonucleotide Class, 2020 - 2033 (US$ Million)
      • 12.3.17.4. Poland Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 12.3.17.5. Poland Market Size and Forecast, By Delivery System, 2020 - 2033 (US$ Million)
      • 12.3.17.6. Poland Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
      • 12.3.17.7. Poland Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 12.3.18. Denmark
      • 12.3.18.1. Overview
      • 12.3.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.3.18.3. Denmark Market Size and Forecast, By Oligonucleotide Class, 2020 - 2033 (US$ Million)
      • 12.3.18.4. Denmark Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 12.3.18.5. Denmark Market Size and Forecast, By Delivery System, 2020 - 2033 (US$ Million)
      • 12.3.18.6. Denmark Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
      • 12.3.18.7. Denmark Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 12.3.19. Rest of Europe
      • 12.3.19.1. Overview
      • 12.3.19.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.3.19.3. Rest of the Europe Market Size and Forecast, By Oligonucleotide Class, 2020 - 2033 (US$ Million)
      • 12.3.19.4. Rest of the Europe Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 12.3.19.5. Rest of the Europe Market Size and Forecast, By Delivery System, 2020 - 2033 (US$ Million)
      • 12.3.19.6. Rest of the Europe Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
      • 12.3.19.7. Rest of the Europe Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
  • 12.4. Asia Pacific (APAC)
    • 12.4.1. Overview
    • 12.4.2. Oligonucleotide Therapeutics Key Manufacturers in Asia Pacific
    • 12.4.3. APAC Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 12.4.4. APAC Market Size and Forecast, By Oligonucleotide Class, 2020 - 2033 (US$ Million)
    • 12.4.5. APAC Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
    • 12.4.6. APAC Market Size and Forecast, By Delivery System, 2020 - 2033 (US$ Million)
    • 12.4.7. APAC Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 12.4.8. APAC Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 12.4.9. China
      • 12.4.9.1. Overview
      • 12.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.4.9.3. China Market Size and Forecast, By Oligonucleotide Class, 2020 - 2033 (US$ Million)
      • 12.4.9.4. China Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 12.4.9.5. China Market Size and Forecast, By Delivery System, 2020 - 2033 (US$ Million)
      • 12.4.9.6. China Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
      • 12.4.9.7. China Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 12.4.10. India
      • 12.4.10.1. Overview
      • 12.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.4.10.3. India Market Size and Forecast, By Oligonucleotide Class, 2020 - 2033 (US$ Million)
      • 12.4.10.4. India Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 12.4.10.5. India Market Size and Forecast, By Delivery System, 2020 - 2033 (US$ Million)
      • 12.4.10.6. India Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
      • 12.4.10.7. India Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 12.4.11. Japan
      • 12.4.11.1. Overview
      • 12.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.4.11.3. Japan Market Size and Forecast, By Oligonucleotide Class, 2020 - 2033 (US$ Million)
      • 12.4.11.4. Japan Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 12.4.11.5. Japan Market Size and Forecast, By Delivery System, 2020 - 2033 (US$ Million)
      • 12.4.11.6. Japan Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
      • 12.4.11.7. Japan Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 12.4.12. South Korea
      • 12.4.12.1. Overview
      • 12.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.4.12.3. South Korea Market Size and Forecast, By Oligonucleotide Class, 2020 - 2033 (US$ Million)
      • 12.4.12.4. South Korea Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 12.4.12.5. South Korea Market Size and Forecast, By Delivery System, 2020 - 2033 (US$ Million)
      • 12.4.12.6. South Korea Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
      • 12.4.12.7. South Korea Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 12.4.13. Australia
      • 12.4.13.1. Overview
      • 12.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.4.13.3. Australia Market Size and Forecast, By Oligonucleotide Class, 2020 - 2033 (US$ Million)
      • 12.4.13.4. Australia Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 12.4.13.5. Australia Market Size and Forecast, By Delivery System, 2020 - 2033 (US$ Million)
      • 12.4.13.6. Australia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
      • 12.4.13.7. Australia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 12.4.14. Indonesia
      • 12.4.14.1. Overview
      • 12.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.4.14.3. Indonesia Market Size and Forecast, By Oligonucleotide Class, 2020 - 2033 (US$ Million)
      • 12.4.14.4. Indonesia Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 12.4.14.5. Indonesia Market Size and Forecast, By Delivery System, 2020 - 2033 (US$ Million)
      • 12.4.14.6. Indonesia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
      • 12.4.14.7. Indonesia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 12.4.15. Thailand
      • 12.4.15.1. Overview
      • 12.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.4.15.3. Thailand Market Size and Forecast, By Oligonucleotide Class, 2020 - 2033 (US$ Million)
      • 12.4.15.4. Thailand Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 12.4.15.5. Thailand Market Size and Forecast, By Delivery System, 2020 - 2033 (US$ Million)
      • 12.4.15.6. Thailand Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
      • 12.4.15.7. Thailand Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 12.4.16. Philippines
      • 12.4.16.1. Overview
      • 12.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.4.16.3. Philippines Market Size and Forecast, By Oligonucleotide Class, 2020 - 2033 (US$ Million)
      • 12.4.16.4. Philippines Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 12.4.16.5. Philippines Market Size and Forecast, By Delivery System, 2020 - 2033 (US$ Million)
      • 12.4.16.6. Philippines Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
      • 12.4.16.7. Philippines Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 12.4.17. Taiwan
      • 12.4.17.1. Overview
      • 12.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.4.17.3. Taiwan Market Size and Forecast, By Oligonucleotide Class, 2020 - 2033 (US$ Million)
      • 12.4.17.4. Taiwan Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 12.4.17.5. Taiwan Market Size and Forecast, By Delivery System, 2020 - 2033 (US$ Million)
      • 12.4.17.6. Taiwan Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
      • 12.4.17.7. Taiwan Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 12.4.18. Vietnam
      • 12.4.18.1. Overview
      • 12.4.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.4.18.3. Vietnam Market Size and Forecast, By Oligonucleotide Class, 2020 - 2033 (US$ Million)
      • 12.4.18.4. Vietnam Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 12.4.18.5. Vietnam Market Size and Forecast, By Delivery System, 2020 - 2033 (US$ Million)
      • 12.4.18.6. Vietnam Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
      • 12.4.18.7. Vietnam Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 12.4.19. Rest of APAC
      • 12.4.19.1. Overview
      • 12.4.19.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.4.19.3. Rest of APAC Market Size and Forecast, By Oligonucleotide Class, 2020 - 2033 (US$ Million)
      • 12.4.19.4. Rest of APAC Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 12.4.19.5. Rest of APAC Market Size and Forecast, By Delivery System, 2020 - 2033 (US$ Million)
      • 12.4.19.6. Rest of APAC Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
      • 12.4.19.7. Rest of APAC Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
  • 12.5. Latin America (LATAM)
    • 12.5.1. Overview
    • 12.5.2. Oligonucleotide Therapeutics Key Manufacturers in Latin America
    • 12.5.3. LATAM Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 12.5.4. LATAM Market Size and Forecast, By Oligonucleotide Class, 2020 - 2033 (US$ Million)
    • 12.5.5. LATAM Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
    • 12.5.6. LATAM Market Size and Forecast, By Delivery System, 2020 - 2033 (US$ Million)
    • 12.5.7. LATAM Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 12.5.8. LATAM Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 12.5.9. Brazil
      • 12.5.9.1. Overview
      • 12.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.5.9.3. Brazil Market Size and Forecast, By Oligonucleotide Class, 2020 - 2033 (US$ Million)
      • 12.5.9.4. Brazil Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 12.5.9.5. Brazil Market Size and Forecast, By Delivery System, 2020 - 2033 (US$ Million)
      • 12.5.9.6. Brazil Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
      • 12.5.9.7. Brazil Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 12.5.10. Mexico
      • 12.5.10.1. Overview
      • 12.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.5.10.3. Mexico Market Size and Forecast, By Oligonucleotide Class, 2020 - 2033 (US$ Million)
      • 12.5.10.4. Mexico Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 12.5.10.5. Mexico Market Size and Forecast, By Delivery System, 2020 - 2033 (US$ Million)
      • 12.5.10.6. Mexico Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
      • 12.5.10.7. Mexico Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 12.5.11. Argentina
      • 12.5.11.1. Overview
      • 12.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.5.11.3. Argentina Market Size and Forecast, By Oligonucleotide Class, 2020 - 2033 (US$ Million)
      • 12.5.11.4. Argentina Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 12.5.11.5. Argentina Market Size and Forecast, By Delivery System, 2020 - 2033 (US$ Million)
      • 12.5.11.6. Argentina Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
      • 12.5.11.7. Argentina Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 12.5.12. Colombia
      • 12.5.12.1. Overview
      • 12.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.5.12.3. Colombia Market Size and Forecast, By Oligonucleotide Class, 2020 - 2033 (US$ Million)
      • 12.5.12.4. Colombia Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 12.5.12.5. Colombia Market Size and Forecast, By Delivery System, 2020 - 2033 (US$ Million)
      • 12.5.12.6. Colombia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
      • 12.5.12.7. Colombia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 12.5.13. Rest of LATAM
      • 12.5.13.1. Overview
      • 12.5.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.5.13.3. Rest of LATAM Market Size and Forecast, By Oligonucleotide Class, 2020 - 2033 (US$ Million)
      • 12.5.13.4. Rest of LATAM Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 12.5.13.5. Rest of LATAM Market Size and Forecast, By Delivery System, 2020 - 2033 (US$ Million)
      • 12.5.13.6. Rest of LATAM Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
      • 12.5.13.7. Rest of LATAM Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
  • 12.6. Middle East and Africa
    • 12.6.1. Overview
    • 12.6.2. Oligonucleotide Therapeutics Key Manufacturers in Middle East and Africa
    • 12.6.3. Middle East and Africa Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 12.6.4. Middle East and Africa Market Size and Forecast, By Oligonucleotide Class, 2020 - 2033 (US$ Million)
    • 12.6.5. Middle East and Africa Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
    • 12.6.6. Middle East and Africa Market Size and Forecast, By Delivery System, 2020 - 2033 (US$ Million)
    • 12.6.7. Middle East and Africa Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 12.6.8. Middle East and Africa Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 12.6.9. Saudi Arabia
      • 12.6.9.1. Overview
      • 12.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.6.9.3. Saudi Arabia Market Size and Forecast, By Oligonucleotide Class, 2020 - 2033 (US$ Million)
      • 12.6.9.4. Saudi Arabia Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 12.6.9.5. Saudi Arabia Market Size and Forecast, By Delivery System, 2020 - 2033 (US$ Million)
      • 12.6.9.6. Saudi Arabia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
      • 12.6.9.7. Saudi Arabia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 12.6.10. United Arab Emirates
      • 12.6.10.1. Overview
      • 12.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.6.10.3. United Arab Emirates Market Size and Forecast, By Oligonucleotide Class, 2020 - 2033 (US$ Million)
      • 12.6.10.4. United Arab Emirates Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 12.6.10.5. United Arab Emirates Market Size and Forecast, By Delivery System, 2020 - 2033 (US$ Million)
      • 12.6.10.6. United Arab Emirates Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
      • 12.6.10.7. United Arab Emirates Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 12.6.11. Israel
      • 12.6.11.1. Overview
      • 12.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.6.11.3. Israel Market Size and Forecast, By Oligonucleotide Class, 2020 - 2033 (US$ Million)
      • 12.6.11.4. Israel Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 12.6.11.5. Israel Market Size and Forecast, By Delivery System, 2020 - 2033 (US$ Million)
      • 12.6.11.6. Israel Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
      • 12.6.11.7. Israel Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 12.6.12. Turkey
      • 12.6.12.1. Overview
      • 12.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.6.12.3. Turkey Market Size and Forecast, By Oligonucleotide Class, 2020 - 2033 (US$ Million)
      • 12.6.12.4. Turkey Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 12.6.12.5. Turkey Market Size and Forecast, By Delivery System, 2020 - 2033 (US$ Million)
      • 12.6.12.6. Turkey Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
      • 12.6.12.7. Turkey Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 12.6.13. Algeria
      • 12.6.13.1. Overview
      • 12.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.6.13.3. Algeria Market Size and Forecast, By Oligonucleotide Class, 2020 - 2033 (US$ Million)
      • 12.6.13.4. Algeria Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 12.6.13.5. Algeria Market Size and Forecast, By Delivery System, 2020 - 2033 (US$ Million)
      • 12.6.13.6. Algeria Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
      • 12.6.13.7. Algeria Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 12.6.14. Egypt
      • 12.6.14.1. Overview
      • 12.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.6.14.3. Egypt Market Size and Forecast, By Oligonucleotide Class, 2020 - 2033 (US$ Million)
      • 12.6.14.4. Egypt Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 12.6.14.5. Egypt Market Size and Forecast, By Delivery System, 2020 - 2033 (US$ Million)
      • 12.6.14.6. Egypt Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
      • 12.6.14.7. Egypt Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 12.6.15. Iran
      • 12.6.15.1. Overview
      • 12.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.6.15.3. Iran Market Size and Forecast, By Oligonucleotide Class, 2020 - 2033 (US$ Million)
      • 12.6.15.4. Iran Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 12.6.15.5. Iran Market Size and Forecast, By Delivery System, 2020 - 2033 (US$ Million)
      • 12.6.15.6. Iran Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
      • 12.6.15.7. Iran Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 12.6.16. Qatar
      • 12.6.16.1. Overview
      • 12.6.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.6.16.3. Qatar Market Size and Forecast, By Oligonucleotide Class, 2020 - 2033 (US$ Million)
      • 12.6.16.4. Qatar Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 12.6.16.5. Qatar Market Size and Forecast, By Delivery System, 2020 - 2033 (US$ Million)
      • 12.6.16.6. Qatar Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
      • 12.6.16.7. Qatar Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 12.6.17. Rest of MEA
      • 12.6.17.1. Overview
      • 12.6.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.6.17.3. Rest of MEA Market Size and Forecast, By Oligonucleotide Class, 2020 - 2033 (US$ Million)
      • 12.6.17.4. Rest of MEA Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 12.6.17.5. Rest of MEA Market Size and Forecast, By Delivery System, 2020 - 2033 (US$ Million)
      • 12.6.17.6. Rest of MEA Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
      • 12.6.17.7. Rest of MEA Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)

13. Key Vendor Analysis- Oligonucleotide Therapeutics Industry

  • 13.1. Competitive Benchmarking
    • 13.1.1. Competitive Dashboard
    • 13.1.2. Competitive Positioning
  • 13.2. Company Profiles
    • 13.2.1. Ionis Pharmaceuticals, Inc.
    • 13.2.2. Alnylam Pharmaceuticals, Inc.
    • 13.2.3. Sarepta Therapeutics, Inc.
    • 13.2.4. Biogen Inc.
    • 13.2.5. Novartis AG
    • 13.2.6. Arrowhead Pharmaceuticals, Inc.
    • 13.2.7. Roche / Genentech
    • 13.2.8. Astellas Pharma Inc.
    • 13.2.9. Nippon Shinyaku Co., Ltd.
    • 13.2.10. Amgen Inc.
    • 13.2.11. Regeneron Pharmaceuticals, Inc.
    • 13.2.12. BioMarin Pharmaceutical Inc.
    • 13.2.13. Moderna, Inc.
    • 13.2.14. Wave Life Sciences Ltd.
    • 13.2.15. Arcturus Therapeutics Holdings Inc.
    • 13.2.16. Avidity Biosciences, Inc.
    • 13.2.17. Silence Therapeutics plc
    • 13.2.18. Nitto Denko Corporation / Nitto Denko Avecia
    • 13.2.19. Stoke Therapeutics, Inc.
    • 13.2.20. Others

14. 360 Degree Analyst View

15. Appendix

  • 15.1. Research Methodology
  • 15.2. References
  • 15.3. Abbreviations
  • 15.4. Disclaimer
  • 15.5. Contact Us